相关临床试验
223
21 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
7
3.1%
已完成
140
62.8%
Enrolling By Invitation
4
1.8%
尚未招募
10
4.5%
招募中
21
9.4%
终止
7
3.1%
Unknown
23
10.3%
撤回
11
4.9%
暂无批准数据
- Penn Medicine has received a $50 million gift from businessman Stanley C. Middleman to support early-stage research into cancer, autoimmune diseases and infectious diseases. - The donation establishes the Middleman Fund and renames Penn's expanded 3600 Civic Center Blvd. building as the Middleman Center, housing the Colton Center for Autoimmunity. - The 217,000-square-foot, $376 million expansion added seven floors with as many as 37 labs, plus a High-Throughput Institute for Discovery and a Biosafety Level 3 lab. - Penn aims to shorten the path from laboratory discovery to market, building on its pioneering work in CAR T cell therapy and mRNA research.
- A phase 1 trial at Fox Chase Cancer Center and Temple University is combining the JAK2 inhibitor pacritinib with the PARP inhibitor talazoparib to treat myelofibrosis patients who no longer respond to standard therapies. - Early results show significant symptom improvement, with severe patients' symptom scores dropping to single digits within three months, alongside clear biological evidence of increased cancer cell death. - The treatment was well tolerated, with patients remaining on therapy for nearly a year without serious side effects requiring discontinuation or dose reduction. - Researchers plan to enroll 24 patients and use single-cell DNA sequencing to track which cancer cell populations persist, guiding future combination strategies.
- Researchers at the University of Chicago developed lipid nanoparticles that deliver mRNA to insulin-producing beta cells, enabling them to express PD-L1 protein for immune protection. - The nanoparticle system successfully delayed type 1 diabetes progression in mouse models and demonstrated effectiveness in both mouse and human beta cells. - Two versions were created, including one tagged with a peptide targeting GLP-1 receptors, with both showing ability to selectively target beta cells without affecting other cell types. - The approach represents a novel strategy focusing on preserving beta cells by enhancing their self-protection rather than suppressing the autoimmune response.
- Researchers at Temple University developed a novel mRNA therapy that delivers the PSAT1 gene to stimulate heart muscle repair and improve cardiac function following heart attack. - The treatment showed striking results in mice, with robust increases in cardiomyocyte proliferation, reduced tissue scarring, improved blood vessel formation, and significantly enhanced heart function and survival. - PSAT1 activates the serine synthesis pathway, reducing oxidative stress and DNA damage while promoting nuclear translocation of β-catenin for cell cycle re-entry in cardiomyocytes. - The modRNA technology provides a flexible platform for gene delivery with high specificity and limited side effects, without integrating into the genome like viral therapies.
